I. Asherova

MAJOR TENDENCIES IN BURKHOLDERIA DIVERSITY CHANGES, INFECTING RUSSIAN PATIENTS WITH CYSTIC FIBROSIS

E. I. Aksenova, N. E. Sharapova, O. Voronina, 2019, Siberian Medical Review.

Cystic fibrosis complicated by multiresistant tuberculosis

I. Asherova, J. Feigelson, Ludmila A. Vasilyeva, 2006, Acta paediatrica.

Inhaled combination of 7% hypertonic saline and 0.1% hyaluronic acid in therapy of patients with cystic fibrosis: results of a Russian observational study

O. Simonova, I. Asherova, E. Amelina, 2018, Russian Pulmonology.

Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study.

B. Strandvik, C. Y. Ooi, C. Colombo, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Personalized Selection of a CFTR Modulator for a Patient with a Complex Allele [L467F;F508del]

A. Polyakov, I. Asherova, A. Voronkova, 2022, Current issues in molecular biology.

Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators.

C. Y. Ooi, C. Colombo, P. Lewindon, 2023, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Consensus “Cystic Fibrosis: definition, diagnostic criteria, treatment” Section “Microbiology and Epidemiology of chronic respiratory infections in cystic fibrosis”

I. Volkov, L. Namazova-Baranova, Намазова Лейла Сеймуровна, 2016 .

Eradication of early P. aeruginosa infection in children <7 years of age with cystic fibrosis: The early study.

F. Ratjen, A. Moeller, G. Angyalosi, 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

The National Consensus Project* «Cystic Fibrosis: Definition, Diagnostic Criteria, and Therapy». Section «Inhalation Therapy» (Abridged)

I. Volkov, L. Namazova-Baranova, L. А. Shabalova, 2014 .